Venous Thromboembolism Clinical Trial
— C-PLANOfficial title:
Measuring the Changes in Clotting Parameters Before and After Medical Abortion
NCT number | NCT04824118 |
Other study ID # | AC20164 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 26, 2021 |
Est. completion date | August 12, 2021 |
Verified date | April 2022 |
Source | NHS Lothian |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women. There is evidence that clotting parameters can take up to 6 weeks to return to normal for women who have had term deliveries, however there is an absence of information on time taken for clotting parameters to normalise following abortion. As such, existing guidelines are based solely on expert opinion and recommend durations of VTE prevention from as short as 7 days, up to 6 weeks following abortion. All women are assessed for risk of VTE, but data are needed to inform an evidence-based approach to prevention of VTE in these women. The findings from this pilot study have the potential to inform clinical guidance and possibly a larger study subsequently.
Status | Completed |
Enrollment | 45 |
Est. completion date | August 12, 2021 |
Est. primary completion date | August 12, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: Group 1: - Pregnant and seeking abortion - Gestation of pregnancy less than 10 weeks - Healthy, no medical conditions Group 2: - Pregnant and seeking abortion - Gestation of pregnancy between 10 and 14 weeks - Healthy, no medical conditions Group 3: - Pregnant and seeking abortion - Gestation of pregnancy between 14 to 20 weeks - Healthy, no medical conditions Group 4: - Non pregnant - Healthy, no medical conditions - Able to speak English independently Exclusion Criteria: All groups: - Unable to give informed consent - Previous or current venous thromboembolism - Current smoker - Personal or family history of thrombophilia or haemophilia - Taking medicines known to affect clotting parameters (e.g. Aspirin) Groups 1-3: - Planning to commence hormonal contraception prior to second blood test. Group 4: - Using hormonal contraception at baseline visit |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Chalmers Centre for Sexual and Reproductive Health | Edinburgh |
Lead Sponsor | Collaborator |
---|---|
NHS Lothian | University of Edinburgh |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clotting Time in Seconds | As measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Primary | Clot Formation Time in Seconds | As measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Primary | Maximal Amplitude in millimeters | On clotting curve as measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Primary | Maximum Lysis of clot in percentage | As measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Primary | Clot Lysis index in percentage | As measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Primary | Lysis time in seconds | As measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Secondary | Prothrombin Time in seconds | Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. | 10-14 days | |
Secondary | Activated Partial Thromboplastin Time in seconds | Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. | 10-14 days | |
Secondary | International Normalised Ratio (INR) | Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. | 10-14 days | |
Secondary | Fibrinogen in grams per litre | Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. | 10-14 days | |
Secondary | Platelet count (x10^9 per litre) | Assessed by laboratory tests between baseline and follow up in Groups 1-3 and in comparison with group 4. | 10-14 days | |
Secondary | Thromboelastography parameters (comparison with non-pregnant group) | Comparison of thromboelastography parameters (as measured using ClotPro device) between Groups 1-3 with Group 4. | 10-14 days | |
Secondary | Serum hCG in units per litre | Comparison of serum hCG levels between baseline and follow up in groups 1-3 | 10-14 days | |
Secondary | Lysis time in seconds | As measured using ClotPro device between baseline and follow up for Groups 1-3. | 10-14 days | |
Secondary | Clot Lysis index in percentage | As measured using ClotPro device comparing Groups 1-3 with Group 4 | 10-14 days | |
Secondary | Maximum Lysis of clot in percentage | As measured using ClotPro device comparing Groups 1-3 with Group 4 | 10-14 days | |
Secondary | Maximal Amplitude in millimeters | As measured using ClotPro device comparing Groups 1-3 with Group 4. | 10-14 days | |
Secondary | Clot Formation Time in Seconds | As measured using ClotPro device comparing Groups 1-3 with Group 4 | 10-14 days | |
Secondary | Clotting Time in Seconds | As measured using ClotPro device comparing Groups 1-3 with Group 4 | 10-14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05347550 -
Examining the Benefit of Graduated Compression Stockings in the Prevention of vEnous Thromboembolism in Low-risk Surgical Patients
|
N/A | |
Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
Completed |
NCT02379806 -
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study
|
Phase 3 | |
Recruiting |
NCT03691753 -
Safety and Efficacy Study of Fitaya Vena Cava Filter
|
N/A | |
Completed |
NCT02197416 -
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
|
Phase 3 | |
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT01895777 -
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
|
Phase 3 | |
Completed |
NCT05897697 -
Assessing Women's Preferences for Postpartum Thromboprophylaxis: the Prefer-Postpartum Study
|
||
Completed |
NCT04735523 -
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736420 -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT04736719 -
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
|
||
Completed |
NCT02912234 -
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
|
Phase 1 | |
Completed |
NCT02746185 -
Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban
|
Phase 3 | |
Completed |
NCT02829957 -
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
|
Phase 2/Phase 3 | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02661568 -
Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)
|
N/A | |
Completed |
NCT02223260 -
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
|
Phase 2 | |
Completed |
NCT01972243 -
Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model
|
||
Completed |
NCT01431456 -
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
|
Phase 3 |